Nightingale Health teams up with Oxford
Finnish Nightingale Health and Oxford University’s Nuffield Department of Population Health have signed an agreement for comprehensive metabolic biomarker profiling.
The collaboration means that Nightingale Health’s proprietary biomarker analysis technology will be installed at the NDPH Wolfson Laboratory at the University of Oxford in the UK.
The aim of NDPH is to generate and disseminate reliable evidence from observational epidemiology and from randomised trials that leads to practicable methods of preventing premature death and disability. Nightingale Health’s biomarker platform provides a way for comprehensive metabolic profiling of large population studies, as the scalable NMR metabolomics platform simultaneously captures over 220 metabolic biomarkers from a single blood sample.
“We are excited to bring our metabolic profiling technology available on-site at University of Oxford to be utilised for world-class science,” says Teemu Suna, CEO and chairman of Nightingale Health, in a release. “The possibility to run routinely and cost-effectively any number of blood samples to gather extensive quantitative metabolic biomarker data creates an unprecedented opportunity for research and clinical applications.”
The University of Oxford hosts blood samples from millions of people. The agreement enables rapid biomarker analyses of blood samples in various flagship projects at Oxford.